These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16875633)

  • 1. [Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma].
    Xiang XJ; He YJ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):298-301. PubMed ID: 16875633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of survivin expression in peripheral T-cell lymphoma].
    Xiang XJ; He YJ; Li YH; Huang H; Xu F
    Ai Zheng; 2006 Jun; 25(6):758-61. PubMed ID: 16764776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.
    Mitrović Z; Ilić I; Aurer I; Kinda SB; Radman I; Dotlić S; Ajduković R; Labar B
    Pathol Oncol Res; 2011 Jun; 17(2):243-7. PubMed ID: 20853074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
    Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
    Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
    Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].
    Zhang HY; Guan ZZ; Wang B; Huang HQ; Xia ZJ; Lin TY
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):381-4. PubMed ID: 18953841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
    Adida C; Haioun C; Gaulard P; Lepage E; Morel P; Briere J; Dombret H; Reyes F; Diebold J; Gisselbrecht C; Salles G; Altieri DC; Molina TJ
    Blood; 2000 Sep; 96(5):1921-5. PubMed ID: 10961895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW; Steidl C; Sehn LH; Gascoyne RD
    Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
    Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
    Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.
    Zhang Y; You X; Liu H; Xu M; Dang Q; Yang L; Huang J; Shi W
    Ann Hematol; 2017 Sep; 96(9):1485-1491. PubMed ID: 28616658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
    Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
    J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
    Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
    Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.